Kite Can Reach Two-Week Yescarta Turn-Around Time After Manufacturing Change

The streamlined process is expected to shorten the turn-around for the CAR-T therapy to about the same time as from an office visit to front-line cancer treatment, Kite Pharma said.

streamlined process
Kite streamlined its CAR-T manufacturing to shave two days off its turn-around process. • Source: Shutterstock

Kite Pharma, Inc. believes there is more room to lower its Yescarta turn-around time even after the US Food and Drug Administration approved a two-day reduction for its CAR-T cancer treatment Yescarta.

The manufacturing supplement that the FDA cleared will allow Kite’s median turn-around time for Yescarta (axicabtagene ciloleucel) to drop from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell & Gene Therapies

More from Advanced Technologies

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

 

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.